Clinical Trials Directory

Trials / Completed

CompletedNCT01968018

A Study of Safety and Effectiveness of Ultracet in Patients With Chronic Cancer Pain

A Study of Safety and Efficacy of Ultracet in Patients With Chronic Cancer Pain

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
35 (actual)
Sponsor
Janssen-Cilag Ltd.,Thailand · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate the analgesic (painkiller) effectiveness and safety of combination of tramadol HCI (37.5 mg)/acetaminophen (325 mg) in the treatment of chronic cancer pain.

Detailed description

This is an open-label (all people know the identity of the intervention) study. A total of 35 participants will be enrolled in this study. Participants will receive tablet of combination of tramadol HCI (37.5 mg)/acetaminophen (325 mg) on Day 1. Participants may increase their daily dosage of study medication as 1 to 2 tablets every 4 to 6 hours as needed for pain relief, up to maximum of 8 tablets per day. Rescue medication consisting of Extra Strength Tylenol (500 mg) 2 tablets daily for the first six days of the Open-label Phase will be allowed so that the total daily dose of acetaminophen will not exceed 4,000 mg. The total duration of the study treatment for each participant will be approximately 6 weeks. Safety will be evaluated by assessment of adverse events, clinical laboratory tests, skin site assessments, vital signs, and physical examination which will be monitored throughout the study.

Conditions

Interventions

TypeNameDescription
DRUGTramadol HCI/acetaminophenParticipants will receive tablet of tramadol HCI (37.5 mg)/acetaminophen (325 mg) on Day 1. Participants may increase their daily dosage of study medication is 1 to 2 tablets every 4 to 6 hours as needed for pain relief up to maximum of 8 tablets per day.

Timeline

Start date
2004-07-01
Primary completion
2007-04-01
Completion
2007-04-01
First posted
2013-10-23
Last updated
2013-10-23

Locations

1 site across 1 country: Thailand

Source: ClinicalTrials.gov record NCT01968018. Inclusion in this directory is not an endorsement.